EpimAb and Medigene Announce Strategic Co-Development of TCR-Guided T Cell Engagers for Solid Tumors
EpimAb Biotherapeutics
Developer of Tumor Bispecific Antibodies
Medigene
Individualized T Cell Therapy Developer
EpimAb Biotherapeutics and Medigene Collaborate to Develop TCR-Mediated TCE Therapy
EpimAb Biotherapeutics, Inc. ("EpimAb" or "EpimAb Biotherapeutics") and Medigene AG (Medigene, FSE: MDG1, Prime Standard) announced that they have reached a strategic collaboration agreement to research and develop T-cell receptor (TCR)-mediated T-cell engaging therapies (TCR-TCE) for the treatment of immune-related diseases, such as solid tumors.
By integrating their respective expertise and covering multiple targets, the collaboration combines Medigene's 3S (sensitivity, specificity, and safety) TCR generation and characterization capabilities with EpimAb Biotherapeutics' proprietary CD3 antibody and T-FIT (TCR Fab-in-Tandem) platform to develop bispecific therapies. These therapies are expected to provide highly specific targeted immune responses while minimizing off-target effects, thereby improving patient outcomes. Both parties are committed to jointly developing TCR-TCE structural molecules with equal ownership.
Mr. Selwyn Ho, CEO of Medigene AG, stated: "We are delighted to collaborate with EpimAb Biotherapeutics and its unique T-FIT platform, leveraging our specialized 3S TCR generation capabilities to develop potentially best-in-class TCR-TCE. This collaborative development agreement further extends Medigene's TCR applications to off-the-shelf TCR-mediated molecules, demonstrating our commitment to establishing value-driven partnerships and expanding our pipeline to address significant unmet patient needs."
"EpimAb looks forward to leveraging Medigene's unique TCR to discover new TCR-TCE," said Dr. Chenbing Wu, Founder and CEO of EpimAb Biotherapeutics: "Together, we will open up new possibilities for our T-FIT and CD3 binding platforms and develop new targeted therapies for cancer patients."
Addressing Critical Unmet Needs in Solid and Hematologic Tumors, Bispecific Therapies Present Significant Opportunities in the Oncology Market. Each year, over 5 million patients worldwide with solid and hematologic tumors having low five-year survival rates are in urgent need of innovative treatments. Bispecific TCR-TCE offers a promising solution by leveraging the human immune system to target and eradicate cancer cells with greater precision.
From 2023 to 2030, the market for these therapies is expected to experience a compound annual growth rate of 40.9%, surpassing an estimated $80 billion by 2030 (https://www.kbvresearch.com/bispecific-antibodies-market/), highlighting the strong interest in this field and reflecting the significant potential of bispecific therapies to improve patient outcomes and revolutionize the landscape of cancer treatment and other disease therapies.
CloseMedigene AG
Medigene AG (FSE:MDG1) is an immuno-oncology platform company dedicated to developing T-cell receptor (TCR)-mediated therapies for the effective elimination of cancer. Its end-to-end platform technology generates optimal 3S (sensitive, specific, and safe) T-cell receptors with unique properties, applicable across various therapeutic modalities such as off-the-shelf TCR-mediated T-cell engager (TCR-TCE) therapy (MDG3010), TCR-NK, and T-cell receptor-engineered T-cell (TCR-T) therapy (MDG1015). For more information, please visit https://medigene.com/
CloseYuShoreEpimAb BiotherapeuticsLifeObject
EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multispecific antibodies. Leveraging extensive in-house research and technical capabilities, including its proprietary bispecific antibody technology platforms FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab), EpimAb Biotherapeutics is advancing a series of unique pipeline projects globally, including innovative preclinical and clinical stage programs aimed at benefiting cancer patients. For more information, please visit: www.epimab.com
CloseInTCR-Mediated T Cell Engager Molecules
TCR-mediated T-cell engagement (TCR-TCE) molecules represent an innovative "off-the-shelf" immunotherapy that utilizes the specificity of TCRs to direct T cells toward cancer cells. Unlike traditional antibodies, TCRs can recognize intracellular and extracellular targets presented as peptide-HLA complexes on cancer cells, thus allowing for a broader range of targeted antigens.
As part of an end-to-end platform, Medigene has discovered natural TCR sequences with high specificity, sensitivity, and safety (3S). These optimized 3S TCRs can then be fused with differentiation cluster 3 (CD3) T cell binding antibodies.
TCR-TCE redirects patients' own T cells specifically to cancer cells by combining 3S TCR with a target (cancer-testis antigen or neoantigen) that is almost exclusively present on tumor cells. When T cells approach cancer cells, they are activated via CD3 receptor antibodies, inducing the release of cytokines and cytotoxic molecules to promote cancer cell killing.
The development of highly specific TCR-TCEs provides 'off-the-shelf' anticancer drugs, which have the potential to achieve anticancer effects similar to or complementary with adoptive cell therapy.
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com
EpimAb Biotherapeutics
Investor Contact
Dr. Gu Xinyi
Phone: +86-21-61951011
Email:IR@epimab.com
BD Contact
TangYeShengBoScholar
Phone: +86-21-61951014
Email: partnering@epimab.com
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors.
The multi-target collaboration combines the respective expertise of each company with Medigene's 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb's proprietary CD3 antibody and T-FIT (TCR-Fab in tandem) platform. The resultant bispecific therapeutics are expected to provide highly specific targeted immune responses with minimized off-target effects and thus, improved patient outcomes. The companies aim to co-develop TCR-TCE constructs, which will be owned equally by both partners.
"We are delighted to partner with EpimAb and their proprietary T-FIT platform, which is well validated with strong clinical data and a number of prominent recent partnering deals, to develop potential best-in-class TCR-TCEs, leveraging our expert 3S TCR generation capabilities," said Selwyn Ho, CEO of Medigene AG. "This co-development agreement further expands the application of Medigene's TCRs into off-the-shelf TCR-guided modalities and underscores our commitment to forging value-driven partnerships that expand our pipeline in areas of high unmet patient need."
"EpimAb is looking forward to discover new TCR-TCEs with Medigene’s unique TCRs," said Chengbin Wu, CEO and Founder of EpimAb. "Together we can open up new possibilities for our T-FIT and CD3 binding platforms to develop novel targeted therapies for cancer patients."
The market for bispecific therapies represents a significant opportunity in the fight against cancer, addressing the critical unmet need in both solid and hematologic tumors. Annually, over 5 million cancer patients worldwide, suffering from solid and hematologic cancers, face low five-year survival rates, highlighting the urgent demand for innovative treatments. Bispecific TCR-TCEs offer a promising solution, leveraging the body's immune system to target and eradicate cancer cells with heightened precision.
The market for these therapies is projected to experience compound annual growth rate of 40.9% from 2023 to 2030, underscoring the robust and accelerating interest in this field. By 2030, the market is estimated to exceed USD80 billion (https://www.kbvresearch.com/bispecific-antibodies-market/), reflecting its substantial potential to improve patient outcomes and revolutionize treatment of cancer and other diseases.
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that can be utilized in multiple therapeutic modalities, such as off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For more information, please visit https://medigene.com/
About EpimAb Biotherapeutics, Inc
EpimAb Biotherapeutics, Inc is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit: www.epimab.com
About TCR-guided T cell engagers
TCR-guided T cell engagers (TCR-TCEs) represent an innovative 'off-the-shelf' immunotherapy that leverages the specificity of TCRs to guide T cells towards cancer cells. Unlike conventional antibodies, TCRs can recognize both intracellular and extracellular targets presented by peptide-HLA complexes on cancer cells, allowing for a broader range of targetable antigens.
As part of its End-To-End Platform, Medigene discovers natural TCR sequences with high specificity, sensitivity and safety (3S). These optimal 3S TCRs can subsequently be merged with a Cluster of Differentiation 3 (CD3) T cell engaging antibody.
The TCR-TCEs specifically redirect the patient’s own T cells towards the cancer cells via binding of the 3S TCR to a target (cancer-testis antigen or neoantigen) that is almost exclusively present on tumor cells. The T cells, when brought into proximity of cancer cells, are activated through the CD3-engaging antibody, leading to release of cytokines and cytotoxic molecules that facilitate cancer cell killing.
Development of highly specific TCR-TCEs provides 'off-the-shelf' anti-cancer agents with potential to achieve similar or complementary anti-cancer effects to those of adoptive cell therapies.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
EpimAb Biotherapeutics, Inc
Investor Contact
Dr. David Gu
Phone: +86-21-61951011
Email: IR@epimab.com
BD Contact
Dr. Jason Tang
Phone: +86-21-61951014
Email: partnering@epimab.com
